Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases, has announced its participation in the Leerink Partners Global Healthcare Conference. The company's management will engage in a fireside chat on March 11, 2025 at 8:40 am ET in Miami, FL.
The presentation will be accessible via webcast through the company's website investor relations section and will remain available for replay for a minimum of 30 days following the event.
Fulcrum Therapeutics (Nasdaq: FULC), un'azienda biofarmaceutica in fase clinica che sviluppa piccole molecole per malattie genetiche rare, ha annunciato la sua partecipazione alla Leerink Partners Global Healthcare Conference. La direzione dell'azienda parteciperà a una chiacchierata informale il 11 marzo 2025 alle 8:40 ET a Miami, FL.
La presentazione sarà accessibile tramite webcast nella sezione relazioni con gli investitori del sito web dell'azienda e rimarrà disponibile per la visione per un minimo di 30 giorni dopo l'evento.
Fulcrum Therapeutics (Nasdaq: FULC), una empresa biofarmacéutica en etapa clínica que desarrolla pequeñas moléculas para enfermedades genéticas raras, ha anunciado su participación en la Leerink Partners Global Healthcare Conference. La dirección de la empresa participará en una charla informal el 11 de marzo de 2025 a las 8:40 am ET en Miami, FL.
La presentación será accesible a través de un webcast en la sección de relaciones con inversores del sitio web de la empresa y estará disponible para su reproducción durante un mínimo de 30 días después del evento.
Fulcrum Therapeutics (Nasdaq: FULC)는 희귀 유전 질환을 위한 소분자를 개발하는 임상 단계의 생명공학 회사로, Leerink Partners Global Healthcare Conference에 참여한다고 발표했습니다. 회사 경영진은 2025년 3월 11일 오전 8시 40분 ET에 플로리다주 마이애미에서 화상 대화에 참여할 예정입니다.
발표는 회사 웹사이트의 투자자 관계 섹션을 통해 웹캐스트로 접근할 수 있으며, 이벤트 이후 최소 30일 동안 다시 볼 수 있습니다.
Fulcrum Therapeutics (Nasdaq: FULC), une entreprise biopharmaceutique en phase clinique développant de petites molécules pour des maladies génétiques rares, a annoncé sa participation à la Leerink Partners Global Healthcare Conference. La direction de l'entreprise participera à une discussion informelle le 11 mars 2025 à 8h40 ET à Miami, FL.
La présentation sera accessible via un webcast dans la section des relations investisseurs du site web de l'entreprise et restera disponible en replay pendant au moins 30 jours après l'événement.
Fulcrum Therapeutics (Nasdaq: FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das kleine Moleküle für seltene genetische Erkrankungen entwickelt, hat seine Teilnahme an der Leerink Partners Global Healthcare Conference bekannt gegeben. Das Management des Unternehmens wird am 11. März 2025 um 8:40 Uhr ET in Miami, FL, an einem informellen Gespräch teilnehmen.
Die Präsentation wird über einen Webcast im Bereich Investor Relations der Unternehmenswebsite zugänglich sein und mindestens 30 Tage nach der Veranstaltung für eine Wiederholung verfügbar bleiben.
- None.
- None.
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on March 11, 2025 at 8:40 am ET.
The webcast of the fireside chat will be accessible HERE and by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
When is Fulcrum Therapeutics (FULC) presenting at the Leerink Partners Conference 2025?
How can investors access Fulcrum Therapeutics' (FULC) Leerink Conference presentation?
How long will the replay of FULC's Leerink Conference presentation be available?
What is the focus of Fulcrum Therapeutics' (FULC) drug development program?
